3Gozzo Tde O,Panobianco MS,Clapis M J. Dermatological toxicity in women with breast cancer undergoingchemotherapy treatment[J].Rev Lat Am Enfermagem,2010,(04):681-687.
4Schulmeister L. Managing vesicant extravasations[J].{H}Oncologist(the)t,2008,(03):284-288.
5Schulmeister L. Preventing and Managing Vesicant Chemotherapy Extravasations[J].J Support Oncol,2010,(05):212-215.
6Wengstr(o)m Y,Margulies A,European Oncology Nursing Society Task Force. European Oncology Nursing Society extravasation guidelines[J].Eur J Oncol Nurs,2008,(04):357-361.
7Reeves D. Management of anthracline extravasation injuries[J].Ann Pharmaeother,2007,(07):1238-1242.
8Muthuramalingam S,Gale J,Bradbury J. Dexrazoxane efficacy for anthracycline extravasation:use in UK clinical practice[J].{H}INTERNATIONAL Journal OF CLINICAL PRACTICE,2013,(03):244-249.
9Schulmeister L. Vesicant chemotherapy extravasation antidotes and treatments[J].{H}Clinical Journal of Oncology Nursing,2009,(04):395-398.
10Zatkóné,Puskás G. The significance of extravasation in oncological care[J].Magy Onkol,2008,(01):75-80.
